2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Technology and Procedures, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

551 Permissive chromosomal instability and TP53 inactivation mark convergent TNFRSF17 loss post anti-BCMA immunotherapy in multiple myeloma

Andrea Poletti, PhD, Holly Lee, MD, PhD2, Sungwoo Ahn, PhD3, Mansour Poorebrahim, PhD4, David Jung, BSc5, Sacha Benaoudia, PhD6, Noemie Leblay, PhD7, Takeshi Yoroidaka, MD, PhD8, Sae Matsuoka9, Elyad Babaei, N/A10, Motamed Mahmoud, PhD11, Anja Barbour, N/A12, Marietta Truger, PhD13, Lawrence H Boise, PhD14, Hermann Einsele, MD, PhD15, Jonathan Keats, PhD16, Efstathios Kastritis, MD17, Hiroyuki Takamatsu, MD18, Francesco Maura, MD19, Benjamin Podvin, PhD20, Salomon Manier, MD, PhD21, Tomas Jelinek Sr, MD22, Sheri Skerget23, Deeksha Vishwamitra, PhD24, Marc-Steffen Steffen Raab, MD25, Niels Weinhold, PhD26, Jill Corre Sr, PharmD27, Leo Rasche Jr, MD28, Hervé Avet-Loiseau, MD, PhD,29, Nikhil Munshi, MD30, Mehmet Kemal Samur, PhD31, Paola Neri, MD, PhD32, Nizar Bahlis, MD33
1 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
2 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
3 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
4 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
5 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
6 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
7 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
8 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
9 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
10 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
11 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
12 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
13 MLL Munich Leukemia Laboratory, Munich, Germany
14 Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
15 University Hospital of Würzburg, Würzburg, Germany
16 Translational Genomics Research Institute, Phoenix, Arizona, United States
17 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
18 Kanazawa University Hospital, Kanazawa, Japan
19 MSKCC, New York, United States
20 Centre Hospitalier Universitaire Lille, Lille University, Lille, France
21 Centre Hospitalier Universitaire Lille, Lille University, Lille, France
22 Ostrava University, Prague, Czech Republic
23 Johnson and Johnson, Spring House, United States
24 Janssen Research & Development, Spring House, United States
25 Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Heidelberg, Germany, United States
26 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Heidelberg, United States
27 University of Toulouse, University Hospital, Unit for Genomics in Myeloma, IUCT Oncopole, CRCT, Toulouse, France
28 University Hospital of Würzburg, Würzburg, Germany
29 UC-T Oncopole, Unité de Génomique du Myélome, Toulouse, France
30 Dana-Farber Cancer Institute, Boston, United States
31 Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Boston, United States
32 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada
33 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada

Introduction: Antigen escape driven by TNFRSF17 biallelic deletion, or monoallelic deletion coupled with extracellular domain mutation is the predominant mechanism of resistance to anti-BCMA T-cell engagers. However, whether theseTNFRSF17 mutations occur stochastically or arise in a uniquely permissive genomic context is unknown. Using whole-genome sequencing (WGS) datasets of CD138+ MM cells from patients treated with anti-BCMA T cell redirecting therapy, we define the genomic landscape of BCMA antigen loss.

Methods: We analyzed 74 tumor WGS from 55 RRMM patients treated with anti-BCMA T cell therapies (29 pre-treatment, 45 at progression; 18 paired). Copy number (CN) was derived from ASCAT, CNVkit and FACETS. Somatic variants (SNVs and indels) were called with Mutect2, Strelka2, Lancet Manta, and SvABA; structural variants (SVs) by Manta, SvABA and Lumpy; and IgH translocations by IgCaller. CN signatures were extracted with SigProfiler, and Palimpsest; genomic scar score using scarHRD, and chromothripsis using ShatterSeek. Antigen escape was defined as any inactivating TNFRSF17 event (CN deletion, coding mutation, or focal SV/breakpoint), and samples were classified as PRE, POST-wild-type (POST-WT) or POST-escape. Groups were compared across 230 covariates, including arm-level and focal CN (GISTIC peaks), mutations, IG translocations, chromothripsis, pathway/gene-level convergent alteration status, and CN/SBS signatures, using Fisher's exact and Kruskal-Wallis tests with Benjamini-Hochberg correction within each covariate, plus logistic models adjusted for primary-refractory status.

Results: BCMA antigen escape was the predominant event observed at progression, occurring in 33 of 45 samples (73%). All three escape mechanisms, CN loss, SVs, and coding mutations, were independently and significantly enriched post-therapy. CN loss increased from 1 of 29 pre-treatment samples to 26 of 45 at progression (p=9.3×10⁻⁷), and SVs increased from 3 of 29 to 27 of 45 (p=2.3×10⁻⁵). Coding TNFRSF17 mutations, absent in pre-treatment samples, were significantly enriched at progression (p=4.9×10⁻⁴), consistent with targeted selective pressure convergent evolution.

Comparing the 3 groups (PRE vs POST-WT vs POST-escape), several mutations emerged specifically in POST-escape samples while remaining at pre-treatment levels in POST-WT. Chromosomal instability (CIN) was enriched in the POST-escape samples. In particular, chr17p arm-loss was detected in 10%, 17% and 36% (p=0.04) of PRE, POST-WT and POST-escape samples respectively, while focal 17p13.1 (TP53) deletion was present in 14%, 17% and 45% (p=0.016). Compared to PRE, focal TP53 loss had an odds ratio (OR) of 5.1 (p=0.012), increasing to 7.4 after excluding primary-refractory samples (p=0.006). COSMIC CN signature 9 (CN9), representing global CIN was also enriched in POST-escape (median: 0%, 34%, 50%, p= 0.012). Consistent with the CN9 enrichment, scarHRD genomic scar score was significantly higher in the POST-escape versus PRE (p=0.008).  Notably, while chromothripsis events were common in POST, they were not detected at the TNFRSF17 locus on chr16p.

NF-kB activating mutations followed a similar pattern of enrichment in POST-WT vs POST-escape: NFKB2 (10q24.32) gain in 8% and 21% (p=0.091) and BIRC2/BIRC3 (11q22.3) deletion in 5% and 17% (p=0.044), respectively. Among POST cases excluding primary refractory, RB1 pathway inactivation was significantly enriched in POST-WT versus POST-escape (100% vs 52%, p=0.006, FDR=0.054), supporting high disease proliferation as an alternate immune escape mechanism in the absence of antigenic loss.  

In COSMIC mutational signature analysis, SBS9 (polymerase eta activity/ somatic hypermutation) was significantly enriched in POST-escape versus POST-WT (p=0.0126, FDR=0.088). APOBEC mutational signature (SBS2+13) was limited to cases with MAF translocation and BCMA antigenic loss, while at the gene level, 1/3 of TNFRSF17 SNVs were attributable to SBS2+13 signature.  

Conclusions: TNFRSF17 inactivation at relapse is frequent and mechanistically convergent, involving CN losses, SVs and inactivating mutations. Beyond the locus itself, escape was accompanied by TP53/17p loss, chromosomal instability (COSMIC CN9), and SBS9 mutational signature. Antigen escape may therefore require a permissive genomic co-alteration rather than occurring stochastically in isolation.
Andrea Poletti, PhD: No relevant conflicts of interest to declare.